Leading HIV scientists launch project to develop HIV vaccine

Leading HIV scientists and researchers have been brought together to accelerate the search for an effective HIV vaccine.

The European AIDS Vaccine Initiative (EAVI2020) is a new EUR 23 million project, financed by the European Commission. Leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA have been brought together in a focused effort to develop a protective and therapeutic HIV vaccine.

Although researchers have been working on developing an HIV vaccine for 30 years, recent advances are helping to speed up their quest. Scientists have isolated antibodies that are able to block HIV infection in preclinical models, and there have been new developments in using synthetic biology to design better vaccines.

According to the World Health Organisation, at the end of 2013 around 35 million people were living with HIV. Every year, over two million people are newly infected and it is estimated that around 22 billion US dollars is spent yearly on HIV treatment and care. An effective HIV vaccine remains the best hope of ending the epidemic.

Led by Imperial College London, the EAVI2020 consortium unites scientists from 22 institutions, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. EAVI2020 is funded with an EU grant under the health program of Horizon 2020 for research and innovation.

EAVI2020 is a unique opportunity, providing the needed breadth of expertise

Professor Robin Shattock, Coordinator of EAVI2020, from the Department of Medicine at Imperial College London, said: “Creating an effective vaccine against HIV represents one of the greatest biological challenges of a generation. This project creates a unique opportunity for us to build on the enormous scientific progress gleaned over the last few years, providing an unprecedented insight into the nature of protective antibodies and anti-viral cellular response that will be needed for an effective vaccine. We now understand much more about how humans make protective immune responses and how to structure vaccine candidates. We have a level of understanding at a molecular level that was not previously available.

“But it is impossible for one group or institution to create an HIV vaccine on its own. This new project should enable us to move much more quickly. It brings together a multidisciplinary team of molecular biologists, immunologists, virologists, biotechnologists and clinicians, providing the breadth of expertise needed to take the latest discoveries in the lab and rapidly advance them through preclinical testing and manufacture, into early human trials.”

At Imperial, researchers will be looking at how healthy human volunteers’ immune systems respond to potential vaccines, studying the antibodies that the volunteers produce. The researchers will explore the pathways in the body that make these antibodies, in order to fine-tune candidate vaccines.

Dr Ruxandra Draghia-Akli, Director of the Health Directorate at the Directorate General for Research and Innovation of the European Commission commented: “In its dual role of policy maker and research funder, the European Commission has played an essential part for over thirty years in supporting HIV vaccine research. Despite major global investments in the field and the promising progress, several scientific obstacles have to be overcome to develop novel promising HIV vaccine candidates. It is with this in mind that the European Commission is providing an almost 23 million Euro grant to the EAVI2020 consortium from which we have high hopes for success. This will allow European scientists to work together and in collaboration with researchers from outside Europe to successfully develop predictive tools and better vaccine candidates to be tested at an early stage of the process”.